Ricevi le ultime notizie sulle azioni BiomX con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di PHGE

Ultime notizie per

BIOMX INC

BiomX

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

BiomX Inc

BiomX Inc Warrants (13/12/2023)

This $13M Biotech Has $40M in Pentagon Funding – Here's Why BiomX Could Be Biotech's Best-Kept Secret

News

Health Care

Markets

Press Releases

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

Market Alert: BiomX Trading Surges Following Phase 2b Trial Initiation in Cystic Fibrosis Program

Earnings

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

Next-Gen Leaders: SIGL, PHGE, OTRK, SGBX – Across Critical Sectors

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference

BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

ARMP

NVDA

OTRK

PHGE

SGBX

Abpro Hldgs

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BioCardia

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Curis

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Edesa Biotech

FibroBiologics

Genprex

Geovax Labs

iBio

Immuron Limited - American Depositary Shares

Immuron

Longeveron

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Lisata Therapeutics

Marker Therapeutics

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Propanc Biopharma

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Soligenix

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Tharimmune

HC Wainwright & Co.

Laidlaw & Co.

Chardan Capital

Comments

BiomX Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO